Modified Pediatric Early Warning Score and Modified PRISA II During COVID-19 Pandemic

May 8, 2021 updated by: Ahmet Kagan Ozkaya, Karadeniz Technical University

The Effectiveness of Modified Pediatric Early Warning Score and Pediatric Hospitalization Risk Scoring II in Patients Applying to the Pediatric Emergency Unit During Pandemic Period Associated With COVID-19 Disease

One of the most important factors in pediatric emergency units is the correct decision of the patient inpatient or outpatient treatment.

If the disease progresses critically, the decision of hospitalization comes to the fore. However, in this case, it is very important to make the right decision and to determine the situation in a short time.

Children give different physiological responses to diseases according to age group. For this reason, some scoring, which require objective parameters, have been developed in order to predict the critical processes of the patients and to intervene at the right time.

While such scoring is frequently used in adult emergency units, it is understood that studies on this issue are not sufficient in pediatric emergency units.

The purpose of our study; To evaluate the population of children admitted to the pediatric emergency unit with the modified Pediatric Early Warning Scoring (mPEUS) and Pediatric Hospitalization Risk Scoring II (PRISA II), to predict hospitalization and discharge from the emergency service, and to demonstrate the effectiveness of the scoring to identify critically ill children in the correct early period.

Study Overview

Status

Recruiting

Conditions

Intervention / Treatment

Detailed Description

Triage is the primary step where the first treatment service of a patient admitted to the emergency unit is initiated.

The purpose of triage in the emergency room is a rapid assessment to determine the order of priority. Emergency service triage systems have been developed mainly to identify the "most urgent" or potentially "critical pediatric" cases and give priority to treatment for these patients.

If the patient's condition is critical in the pediatric emergency unit, the decision for outpatient treatment / hospitalization should be made quickly but in the most correct way. Regardless of the diagnosis, the main problem is; early diagnosis of the critical patient, directing the patient to the appropriate area in the emergency department for acute stabilization, and more importantly, to decide quickly whether the patient will be hospitalized in order to continue the treatment and accelerate the flow of the emergency service. It is known that children who unexpectedly worsen in the hospital environment will have observable features in the period before the seriousness of their condition is understood. It has been emphasized in the studies conducted that ways to understand early whether there is a problem in a child should be investigated. For this reason, some scores that require objective parameters have been developed in order to predict the critical processes of the patients and to intervene at the right time. These scores should be viewed not only as a score, but as a complementary systematic approach used to improve pediatric patient safety and clinical outcomes. mPEUS; These are physiology-based scoring systems developed to identify patients with clinical worsening. Studies have reported that with these scores, the treatment of critical emergency patients can be started without delay. mPEUS has been developed to provide a reproducible assessment of the pediatric patient's condition based on physiological parameters. In addition, the use of these scores in the emergency service and inpatient services ensures continuity in patient evaluation. To date, there are very few data regarding the use of mPEUS in children presenting to the emergency department. Although many mPEUS have been developed and tested, uncertainty remains as to which system or system feature is most beneficial for pediatric patients. Therefore, studies on this subject should be increased. mPEUS is an essential tool for patient safety. The use of mPEUS during the initial evaluation can help prevent poor neurological results, deterioration of the patient's condition, and reduce mortality with rapid intervention. In limited studies conducted in pediatric emergency units, it has been shown that these early warning scores can determine the children who need to be admitted to the Pediatric Intensive Care Unit (PICU). With this scoring, the early hospitalization of the patient in the emergency room can be accurately predicted. Such early warning scoring can be used to shorten patients' hospitalization and waiting times in emergency rooms. The PRISA II system, similar to mPEUS but used only to predict inpatients, has also been developed. This scale includes initial history, physiological parameters, chronic disease status, treatments applied in the emergency department and laboratory values. It is appropriate to use PRISA II to control the severity of the disease. There is not enough data in the literature regarding the efficacy of both mPEUS and PRISA II scoring in the epidemic period associated with COVID-19. With this study, it is aimed to provide efficiency by using these scoring in patients who applied to the pediatric emergency unit during the pandemic period.

Study Type

Observational

Enrollment (Anticipated)

894

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact Backup

Study Locations

      • Trabzon, Turkey, 9061080
        • Recruiting
        • Karadeniz Technical University Faculty of Medicine Farabi Hospital
        • Contact:
        • Contact:

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

4 weeks to 18 years (Child, Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Sampling Method

Non-Probability Sample

Study Population

pediatric patients aged between 28 days and 18 years who applied to the Pediatric Emergency Unit

Description

Inclusion Criteria:

- Pediatric patients aged between 28 days and 18 years, who applied to the Pediatric Emergency Unit

Exclusion Criteria:

  • In the follow-up or at the begining, patients who are presenting with cardiorespiratory arrest
  • Intubated patients,
  • Trauma patients
  • Neonatal period (<28 days),
  • Patients who leave the hospital at the request of their family before the end of the diagnosis or treatment process
  • Patients who do not have permission from their parents at the beginning

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Observational Models: Other
  • Time Perspectives: Prospective

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
pediatric patients
whole pediatric patients who admitted to the pediatric emergency unit in Farabi Hospital, Trabzon, Turkey
no intervention

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
modified pediatric early warning score
Time Frame: 1 February - 31 July 2021,
modified pediatric early warning score for each child during Severe Acute Respiratory Syndrome Causing Coronavirus Disease
1 February - 31 July 2021,
mPRISA II
Time Frame: 1 February - 31 July 2021
mPRISA II score for each child during COVID-19 pandemic
1 February - 31 July 2021
Changes in modified pediatric early warning score over time
Time Frame: 1 February - 31 July 2021
Changes in modified pediatric early warning score over time will measure. Early warning score will be calculated every three hours and if the score increases, it will be evaluated more frequently, up to 24 hours.
1 February - 31 July 2021

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Length of stay in pediatric emergency
Time Frame: 1 February - 31 July 2021
Length of stay in pediatric emergency
1 February - 31 July 2021
number of children who returned to the emergency service
Time Frame: 1 February - 31 July 2021
number of children who returned to the emergency service
1 February - 31 July 2021
which service is admitted to
Time Frame: 1 February - 31 July 2021
pediatric wards
1 February - 31 July 2021
number of children with severe acute respiratory syndrome coronavirus 2
Time Frame: 1 February - 31 July 2021
Children diagnosed with COVID-19 (real time PCR positive children)
1 February - 31 July 2021
children who contacted the person with COVID-19
Time Frame: 1 February - 31 July 2021
number and status of children who contacted the person with COVID-19
1 February - 31 July 2021
history of COVID-19 in the past
Time Frame: 1 February - 31 July 2021
number of children who had COVID-19 in the past
1 February - 31 July 2021

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Study Director: Ahmet K Özkaya, MD, phD, Karadeniz Technical University Faculty of Medicine
  • Principal Investigator: Bihter Şen Şahin, MD, Karadeniz Technical University Faculty of Medicine

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

February 1, 2021

Primary Completion (Anticipated)

July 31, 2021

Study Completion (Anticipated)

September 15, 2021

Study Registration Dates

First Submitted

May 3, 2021

First Submitted That Met QC Criteria

May 3, 2021

First Posted (Actual)

May 7, 2021

Study Record Updates

Last Update Posted (Actual)

May 12, 2021

Last Update Submitted That Met QC Criteria

May 8, 2021

Last Verified

May 1, 2021

More Information

Terms related to this study

Other Study ID Numbers

  • KTU-PediEM01

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

No

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Critical Illness

Clinical Trials on no intervention

3
Subscribe